MTA2

Across TCGA pan-cancer cohorts, MTA2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTA2 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MTA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, LAML, and LUAD are the cancer types where MTA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	0.216	0.736	<.001	13	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
LUAD	DFS	Median	All	0.128	0.792	<.001	12	view →
COAD	DFS	Median	All	0.386	0.802	<.001	8	view →
UCEC	OS	Median	All	1.000	0.662	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTA2–SKCM (OS)

Open the SKCM breakdown →